Ceftazidime SodiumThird Party Manufacturing in India

Ceftazidime Sodium works by inhibiting bacterial cell wall synthesis in a broad spectrum of gram-negative and select gram-positive pathogens. As a third-generation cephalosporin, it exhibits high affinity for penicillin-binding proteins, particularly PBP3 and PBP1a, located in the bacterial cell wall membrane. By binding to these enzymes, ceftazidime blocks the final transpeptidation stage of peptidoglycan synthesis, which is crucial for structural wall strength. This enzymatic inhibition leads to cell wall division failure, cell elongation, and rapid osmotic lysis, resulting in bactericidal action. A key feature of ceftazidime is its excellent stability against most plasmid-mediated and chromosomal beta-lactamases, allowing it to remain active against bacteria that degrade other cephalosporins. It is particularly renowned for its potent activity against Pseudomonas aeruginosa, outperforming many other third-generation agents. The drug is poorly absorbed orally, requiring intravenous or intramuscular administration to achieve therapeutic plasma levels. Its high renal excretion profile makes it especially effective for complicated urinary tract infections.

Therapeutic Uses

Ceftazidime Sodium is prescribed for the treatment of:

• Pseudomonal Infections: The drug of choice for severe infections caused by Pseudomonas aeruginosa.
• Lower Respiratory Tract Infections: Treats nosocomial pneumonia, lung infections in cystic fibrosis, and chronic bronchitis.
• Complicated Urinary Tract Infections: Prescribed for severe pyelonephritis, renal abscesses, and prostatitis.
• Intra-abdominal Infections: Indicated for peritonitis and pelvic inflammatory disease in combination with anaerobic cover.
• Meningitis: Treats bacterial meningitis due to excellent cerebrospinal fluid penetration during inflammation.
• Septicemia: Used to treat systemic bacteremia and bloodstream infections.

Why Manufacturers Choose Ceftazidime Sodium

Ceftazidime Sodium is a cornerstone hospital-grade antibiotic on the WHO Model List of Essential Medicines. Its distinct clinical profile, particularly its efficacy against Pseudomonas aeruginosa, guarantees sustained demand globally. Indian pharmaceutical manufacturers produce ceftazidime in large quantities for domestic healthcare institutions and major export markets in Europe, the Middle East, and Africa. Because it is a sterile dry powder injectable, manufacturing requires cleanroom infrastructure and WHO-GMP compliance, which builds trust with international procurement agencies. This makes Ceftazidime Sodium one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.